So-Deok Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
So-Deok Lee has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Daina Martínez-Falguera
Unitat de Farmacologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, c./St. Llorenç 21, E-43201 Reus, Spain
1 shared publication - Francesc Xavier Sureda
Department of Basic Medical Sciences, Universitat Rovira i Virgili, C/Sant Llorenç 21, 43201 Reus, Spain
1 shared publication - Marta Barniol-Xicota
Laboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain
1 shared publication - Olga Karoutzou
Division of Pharmaceutical Chemistry Department of Pharmacy National and Kapodistrian University of Athens Athens Greece
1 shared publication - Santiago Vázquez
Universitat de Barcelona
1 shared publication - Seung-Hwa Kwak
School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Cheomdangwagi-ro, Buk-gu, 123, Gwangju 61005, Korea
1 shared publication
Latest Publications
- Open Access
Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists
Multi-target-directed ligands (MTDLs) offer new hope for the treatment of multifactorial complex diseases such as Alzheimer’s Disease (AD). Herein, we present compounds aimed at targeting the NMDA and the P2X7 receptors, which embody a different approach to AD therapy. On one hand, we are seeking to delay neurodegeneration targeting the glutamatergic NMDA receptors; on the other hand, we also aim to reduce neuroinflammation, targeting P2X7 receptors. Although the NMDA receptor is a widely recognized therapeutic target in treating AD, the P2X7 receptor remains largely unexplored for this purpose; therefore, the dual inhibitor presented herein—which is open to further optimization—represents the first member of a new class of MTDLs.
Open AccessTowards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists
Multi-target-directed ligands (MTDLs) offer new hope for the treatment of multifactorial complex diseases such as Alzheimer’s Disease (AD). Herein, we present compounds aimed at targeting the NMDA and the P2X7 receptors, which embody a different approach to AD therapy. On one hand, we are seeking to delay neurodegeneration targeting the glutamatergic NMDA receptors; on the other hand, we also aim to reduce neuroinflammation, targeting P2X7 receptors. Although the NMDA receptor is a widely recognized therapeutic target in treating AD, the P2X7 receptor remains largely unexplored for this purpose; therefore, the dual inhibitor presented herein—which is open to further optimization—represents the first member of a new class of MTDLs.